EGFR and heart failure: Osimertinib was shown to have a favorable safety profile compared to first-generation EGFR-TKIs, with a lower incidence of adverse event grade = 3 (42% vs 47%), however, the incidence of cardiotoxicity was increased in the osimertinib-treated group, and an analysis of the FDA’s adverse events database found that osimertinib raised the incidence of atrial fibrillation, ECG QT interval prolongation, and heart failure compared with first- or second-generation EGFR-TKIs (29).